Scienture (SCNX) said Thursday its Scienture LLC unit signed an agreement with Summit Biosciences for the exclusive rights to commercially launch Rezenopy, a 10mg naloxone HCl nasal spray for opioid overdose treatment in the US.
Financial details weren't disclosed.
Under the terms of the agreement, Kindeva Drug Delivery, the parent company of Summit Biosciences, will manufacture and supply Rezenopy nasal spray 10mg, while Scienture will retain ownership of the New Drug Application for Rezenopy and oversee US sales, marketing, and distribution.
Shares of Scienture jumped more than 31% in recent Thursday trading.
Price: 2.83, Change: +0.62, Percent Change: +28.05
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。